

For Immediate Release
For Further Information Contact:
Tony Balda at (321) 676-0010 Ext. 2020
Email: info@medicompinc.com

MEDICOMP ANNOUNCES FDA APPROVAL OF NEW HEART MONITOR

Melbourne, FL, April 26, 2005: Medicomp Inc., a wholly-owned subsidiary of United Therapeutics Corporation, announced today that it has received FDA approval to market its newest ambulatory heart monitor, the CardioPAL SAVI™.

The CardioPAL SAVI monitor relies on artificial intelligence to continually monitor the patient's heart, capturing electrocardiogram (ECG) data from symptomatic patients while automatically recording asymptomatic ECG irregularities based on unusual rates, rhythms, or morphologies (waveform shapes). In addition, the SAVI utilizes the powerful Diogenes SV algorithm to perform real-time supraventricular (top chambers of the heart) analysis. It is the *first* ambulatory device to detect the p-wave, a diminutive but critical portion of the ECG that represents atrial activity. SAVI is the perfect combination of artificial intelligence and supraventricular analysis.

"We are excited to be able to offer the most advanced cardiac monitor into the field of ambulatory arrhythmia care, said Martine Rothblatt, Ph.D., United Therapeutics' Chairman and CEO. "This new product exemplifies Medicomp's commitment to providing cardiologists with amazing new tools that significantly enhance patient care. We will continue to push the technology envelope in the years ahead with wireless cardiac monitors."

"With the ability to reliably detect the p-wave, Medicomp will be able to deliver services that help even more patients," said Dan Balda, MD, Medicomp's President. "According to recent studies, 25% of all adults over the age of 40 will develop atrial fibrillation within their lifetime. Our new monitor is uniquely qualified to identify these patients even in the absence of symptoms – we believe it is a real breakthrough," concluded Dr. Balda.

Founded in Florida in 1981, Medicomp specializes in providing proprietary cardiac telemedicine services throughout the United States.

United Therapeutics, a biotechnology company focused on the development and commercialization of unique products for patients with chronic and life-threatening cardiovascular, cancer and infectious diseases.